Boston Common Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Boston Common Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.68M	Buy	19,493 +2,288	+13%	+$1.01M	0.57%	50
2026 Q1	$7.68M	Buy	17,205 +1,124	+7%	+$524K	0.49%	64
2025 Q4	$7.29M	Sell	16,081 -24,818	-61%	-$10.7M	0.44%	70
2025 Q3	$16M	Sell	40,899 -5,164	-11%	-$2.16M	0.45%	76
2025 Q2	$20.5M	Sell	46,063 -4,900	-10%	-$2.26M	0.57%	59
2025 Q1	$24.7M	Buy	50,963 +671	+1%	+$313K	0.75%	41
2024 Q4	$20.3M	Buy	50,292 +26	+0.1%	+$12.1K	0.59%	59
2024 Q3	$23.4M	Buy	50,266 +13,008	+35%	+$6.25M	0.61%	53
2024 Q2	$17.5M	Sell	37,258 -2,061	-5%	-$895K	0.45%	86
2024 Q1	$16.4M	Sell	39,319 -16,038	-29%	-$6.78M	0.39%	97
2023 Q4	$22.5M	Sell	55,357 -2,670	-5%	-$986K	0.51%	74
2023 Q3	$20.2M	Sell	58,027 -1,210	-2%	-$423K	0.48%	78
2023 Q2	$20.8M	Sell	59,237 -15,499	-21%	-$5.22M	0.45%	83
2023 Q1	$23.5M	Sell	74,736 -2,568	-3%	-$770K	0.49%	72
2022 Q4	$22.3M	Buy	77,304 +2,027	+3%	+$618K	1.07%	27
2022 Q3	$21.8M	Buy	75,277 +20,308	+37%	+$5.84M	1.14%	27
2022 Q2	$15.5M	Buy	54,969 +23,085	+72%	+$6.18M	0.77%	44
2022 Q1	$8.32M	Buy	31,884 +844	+3%	+$200K	0.36%	89
2021 Q4	$6.82M	Sell	31,040 -505	-2%	-$98.2K	0.28%	99
2021 Q3	$5.72M	Sell	31,545 -169	-0.5%	-$33K	0.25%	100
2021 Q2	$6.39M	Buy	31,714 +7,635	+32%	+$1.6M	0.27%	94
2021 Q1	$5.17M	Buy	+24,079	New	+$5.29M	0.33%	89

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Boston Common Asset Management's VRTX Position: Q2 2026 in Review

Boston Common Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $1.01M and bringing the position to 19,493 shares worth $9.68M. The position accounts for 0.57% of the portfolio, ranked #50.

Boston Common Asset Management first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $24.7M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Boston Common Asset Management held 19,493 shares of Vertex Pharmaceuticals worth $9.68M as of Q2 2026.
Boston Common Asset Management bought 2,288 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
Vertex Pharmaceuticals made up 0.57% of Boston Common Asset Management's portfolio in Q2 2026, its #50 holding.
Boston Common Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Boston Common Asset Management's Vertex Pharmaceuticals position peaked at $24.7M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Boston Common Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.